Valuation: Haleon plc

Market Cap 29.45B 39.24B 35.19B 32.43B 55.74B 3,679B 57.3B 388B 155B 1,971B 147B 144B 6,231B P/E 2026 *
17.5x
P/E 2027 * 15.6x
Enterprise Value 36.59B 48.75B 43.72B 40.29B 69.25B 4,571B 71.19B 482B 192B 2,449B 183B 179B 7,742B EV / Sales 2026 *
3.24x
EV / Sales 2027 * 3.1x
Free-Float
98.31%
Yield 2026 *
2.4%
Yield 2027 * 2.63%
1 day+0.03%
1 week-0.95%
Current month+4.70%
1 month-5.75%
3 months-8.48%
6 months+2.23%
Current year-10.78%
1 week 329
Extreme 329
344.1
1 month 310.5
Extreme 310.5
433.6
Current year 310.5
Extreme 310.5
433.6
1 year 310.5
Extreme 310.5
433.6
3 years 274.4
Extreme 274.4
433.6
5 years 241.17
Extreme 241.1735
433.6
10 years 241.17
Extreme 241.1735
433.6
Manager TitleAgeSince
Chief Executive Officer 59 2021-07-21
Director of Finance/CFO 58 2024-10-31
Chief Tech/Sci/R&D Officer 63 2025-07-31
Director TitleAgeSince
Director/Board Member 59 2022-05-22
Chairman 71 2025-12-31
Director/Board Member 59 2022-07-17
Date Insider Type Main position Quantity % Market Cap. Importance
10/30/26 Buy

Director

7,670 0.0001%
9/22/26 Buy 2,139 0.0000%
9/22/26 Buy 12,209 0.0001%
Change 5-day change 1-year change 3-year change Capi.($)
+0.01%-0.95%-10.73%+3.55% 39.24B
+1.44%+1.63%+48.17%+139.63% 1,276B
-0.47%+5.49%+49.03%+90.68% 676B
+0.20%+2.76%+34.37%+112.06% 519B
-0.66%+0.91%+38.38%+67.33% 388B
-0.48%+2.34%+70.66%+46.02% 365B
-1.03%-0.76%+28.02%+57.46% 307B
-0.17%-1.03%+3.07%+35.44% 287B
0.00%+0.86%+43.74%+74.04% 252B
+0.92%+2.03%+44.62%+125.07% 212B
Average -0.39%+2.39%+34.93%+75.13% 432B
Weighted average by Cap. -0.62%+2.51%+42.27%+95.73%

Financials

2026 *2027 *
Net sales 11.29B 15.04B 13.49B 12.43B 21.37B 1,410B 21.96B 149B 59.3B 756B 56.45B 55.25B 2,388B 11.66B 15.54B 13.93B 12.84B 22.07B 1,457B 22.69B 154B 61.25B 780B 58.3B 57.07B 2,467B
Net income 1.67B 2.23B 2B 1.84B 3.16B 209B 3.25B 22.02B 8.77B 112B 8.35B 8.17B 353B 1.85B 2.47B 2.21B 2.04B 3.51B 231B 3.6B 24.42B 9.73B 124B 9.26B 9.07B 392B
Net Debt 7.14B 9.51B 8.53B 7.86B 13.51B 892B 13.89B 94.12B 37.5B 478B 35.69B 34.94B 1,510B 6.67B 8.88B 7.97B 7.34B 12.62B 833B 12.97B 87.9B 35.02B 446B 33.34B 32.63B 1,411B
Projected Income Statement - Annual - Haleon plc
Logo Haleon plc
Haleon plc specializes in the research, manufacture and marketing of drugs and consumer pharmaceutical products. Net sales break down by family of products as follows: - oral health products (31.4%; no. 1 worldwide): Sensodyne, Parodontax, Polident, Biotene, Aquafresh brands, etc.; - pain relief medicines (23.2%; no. 1 worldwide): Panadol, Advil, Voltaren, Excedrin brands, etc.; - respiratory medicines (17%; no. 1 worldwide): Theraflu, Otrivin, Flonase, Contac brands, etc.; - vitamins, minerals and food supplements (15.3%; no. 1 worldwide): Centrum, Emergen-C, Caltrate brands, etc.; - medicines for digestive health (8.9%; no. 1 worldwide): TUMS, Nicorette, ENO, Chap Stick, Fenistil, Nexium brands, etc.; - other (4.2%). Net sales are distributed geographically as follows: Europe/Middle East/Africa/Latin America (41.6%), North America (35.1%), and Asia/Pacific (23.3%).
Employees
24,535
Date Price Change Volume
26-11-11 GBX 334.50 -0.15% 7,650,070
26-11-10 GBX 335.00 +1.27% 49,235,014
26-11-09 GBX 330.80 -2.39% 59,983,553
26-11-06 GBX 338.90 -0.53% 41,825,204
26-11-05 GBX 340.70 +0.92% 76,891,722
Trader
Investor
Global
Quality
ESG MSCI
AAA
MarketScreener Ratings - Haleon plc
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
3.350GBP
Average target price
3.759GBP
Spread / Average Target
+12.21%